The Company's presentation is readily accessible at https://www.oncotelic.com/wp-content/uploads/2023/05/BIO-2023-V2.pdf
Key points of the presentation include:
- The significant role of TGF-β2 as the primary driver of survival, outpacing the influence of TGF-β1 and TGF-β3.
- The ongoing advancement of clinical trials for OT-101 in conjunction with P201 in Pancreatic Cancer, set to commence in the second half of 2023. Additional combination trials with various checkpoint inhibitors involving multiple cancer types are also slated to begin within the same timeframe.
- The sustained progress towards the IPO of the joint venture, contingent on favorable market conditions.
- The evolution of a state-of-the-art AI-driven nanomedicine platform designed to bolster both internal developmental processes and external collaborative endeavors.
"Our commitment to innovation is reflected in the development of a cutting-edge AI-driven nanomedicine platform. This platform is anticipated to revolutionize the drug development initiatives within both Oncotelic and the joint venture. We are stand ready to invest in our partners supporting their journey from initial concept to clinical trials and through to commercialization," stated Dr.
We extend a warm invitation to all interested parties to explore the details of our presentation and discover more about the future of our groundbreaking work in rare and orphan disease therapeutics.
About Oncotelic
Oncotelic (f/k/a
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2Dao, the actual filing of a registration statement and approval of the tokens as registrable securities with the
Contact Information:
For
Investor Relations
ir@oncotelic.com
Source:
2023 GlobeNewswire, Inc., source